# CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML

> **NCT05558124** · PHASE1 · RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 18 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Vyxeos
- **DRUG:** Gemtuzumab Ozogamicin

## Key facts

- **NCT ID:** NCT05558124
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-16
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-02-27

## Collaborators

- Jazz Pharmaceuticals

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05558124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05558124, "CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05558124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*